董事会审计委员会议事规则 第一章 总 则 第一条 为强化董事会审计监控功能，做到事前审计、专门审计，确保董事会 对经理层的有效指导和监督，完善公司治理结构，根据《中华人民共和国公司法》 《上市公司独立董事管理办法》《上市公司治理准则》《上海证券交易所股票上市 规则》《马应龙药业集团股份有限公司章程》（以下简称"《公司章程》"）及其他有 关规定，公司设立董事会审计委员会，并制定本议事规则。 第二条 审计委员会是董事会下设的专门委员会，主要负责审核公司财务信息 及其披露、监督及评估公司内外部审计工作和内部控制。 第二章 人员组成 第三条 审计委员会成员由三到五名董事组成，其中独立董事应当过半数，审 计委员会设主任委员一名，并由独立董事中会计专业人士担任召集人（主任委员）。 审计委员会成员应当为不在公司担任高级管理人员的董事。 马应龙药业集团股份有限公司 第四条 审计委员会委员、主任委员由董事会选举产生。 第五条 审计委员会任期与董事会一致，委员任期届满，连选可以连任。期间 如有委员不再担任公司董事职务，自动失去委员资格，并由董事会根据上述第三 至第四条规定增补新委员。 第六条 审计委员会下设审计工作办公室，主要负 ...

马应龙药业集团股份有限公司 董事会议事规则 第一条 宗旨 为了进一步规范本公司董事会的议事方式和决策程序，促使董事和董事会有 效地履行其职责，提高董事会规范运作和科学决策水平，根据《中华人民共和国 公司法》（以下简称《公司法》）、《中华人民共和国证券法》（以下简称《证券法》）、 《上市公司治理准则》、《上海证券交易所股票上市规则》及《公司章程》的有关 规定，制订本规则。 第二条 董事会秘书处 董事会下设董事会秘书处，处理董事会日常事务。保管董事会和董事会秘书 处印章。 第三条 定期会议 董事会每年至少召开两次会议，由董事长召集，于会议召开 10 日以前书面通 知全体董事。 第四条 定期会议的提案 在发出召开董事会定期会议的通知前，董事会秘书处应当充分征求各董事的 意见，初步形成会议提案后交董事长拟定。 董事长在拟定提案前，应当视需要征求经理和其他高级管理人员的意见。 第五条 临时会议 有下列情形之一的，董事会应当召开临时会议： （五）二分之一以上独立董事提议时； （六）经理提议时； 1 （一）代表十分之一以上表决权的股东提议时； （二）三分之一以上董事联名提议时； （三）审计委员会提议时； （四）董事长认为必 ...

马应龙药业集团股份有限公司 董事会秘书工作细则 第一章 总则 第一条 为完善公司法人治理结构，加强对董事会秘书工作的管理与监督， 充分发挥董事会秘书的作用，根据《中华人民共和国证券法》、《上海证券交易 所股票上市规则》（以下简称《股票上市规则》）、《上海证券交易所上市公司 自律监管指引第 1 号——规范运作》等有关法律、法规、规范性文件以及《公司 章程》的规定，结合公司实际情况，制定本工作细则。 第二条 公司设董事会秘书一名。董事会秘书是公司的高级管理人员，分管 信息披露部门及公司要求的其他部门，是公司与交易所之间的指定联络人。董事 会秘书应忠实、勤勉地履行职责，对公司和董事会负责。 第三条 公司董事会在聘请董事会秘书的同时，至少委任一名证券事务代表， 协助董事会秘书履行职责。在董事会秘书不能履行职责时，由证券事务代表行使 其权利并履行其职责，在此期间，并不当然免除董事会秘书对公司信息披露事务 所负有的责任。 第四条 公司证券事务代表参照本细则予以执行。 第二章 董事会秘书的任职资格 第五条 公司董事会秘书应具有下列任职资格： （一）具备履行职责所必需的财务、管理、法律等专业知识；具有良好的个 人品质和职业道 ...

马应龙药业集团股份有限公司 独立董事工作细则 第一章 总 则 第一条 为进一步完善马应龙药业集团股份有限公司（以下简称"公司"）的治理结构， 维护公司全体股东及利益相关者的合法权益，促进公司的规范运作，根据《中华人民共和 国公司法》（以下简称《公司法》）《上市公司独立董事管理办法》《上市公司治理准则》《上 海证券交易所股票上市规则》及《马应龙药业集团股份有限公司章程》）（以下简称《公司 章程》）等有关规定，制定本细则。 第二条 独立董事是指不在公司担任除董事外的其他职务，并与其所受聘的公司及其 主要股东、实际控制人不存在直接或者间接利害关系，或者其他可能妨碍其进行独立客观 判断的关系的董事。 第三条 独立董事对公司及全体股东负有忠实与勤勉义务。独立董事应当按照相关法 律法规、中国证券监督管理委员会（以下简称中国证监会）规定、证券交易所业务规则和 《公司章程》的要求，认真履行职责，在董事会中发挥参与决策、监督制衡、专业咨询作 用，维护公司整体利益，尤其要关注中小股东的合法权益不受损害。 独立董事应当独立履行职责，不受公司及其主要股东、实际控制人或者其他与公司存 在利害关系的单位或个人的影响。 第四条 公司聘任的 ...

马应龙药业集团股份有限公司 第一条 为了加强马应龙药业集团股份有限公司（以下简称"公司"）的信息披露管理 工作，确保正确履行信息披露义务，保护公司、股东、债权人及其他利益相关人的合法权 益，根据《中华人民共和国公司法》、《中华人民共和国证券法》、《上市公司信息披露管理 办法》、《上海证券交易所股票上市规则》等法律、法规、规章以及规范性文件的规定，结 合本公司实际情况，制定本制度。 第二条 信息披露义务人应当及时依法履行信息披露义务，披露的信息应当真实、准 确、完整，简明清晰、通俗易懂，不得有虚假记载、误导性陈述或者重大遗漏。 信息披露事务管理制度 第一章 总则 信息披露义务人披露的信息应当同时向所有投资者披露，不得提前向任何单位和个人 泄露。但是，法律、行政法规另有规定的除外。 公司的董事、高级管理人员应当忠实、勤勉地履行职责，保证披露信息的真实、准确、 完整，信息披露及时、公平。 第三条 在内幕信息依法披露前，任何知情人和非法获取内幕信息的人不得公开或者 泄露该信息，不得利用该信息进行内幕交易。 第四条 公司信息披露文件主要包括招股说明书、募集说明书、定期报告、临时报告、 上市公告书、收购报告书等。 第二章 ...

马应龙公告，第三季度营收为8.88亿元，同比增长2.80%；净利润为1.58亿元，同比增长8.38%。前三季 度营收为28.37亿元，同比增长1.63%；净利润为5.01亿元，同比增长9.51%。 ...

Summary of the Conference Call for Mayinglong Company Overview - Mayinglong focuses on pharmaceutical products such as hemorrhoid ointments and suppositories, as well as medical services and pharmaceutical commerce. The core products are hemorrhoid ointments and suppositories, with involvement in dermatology, ophthalmology, and other health categories [2][3]. Key Points and Arguments - **Growth in Hemorrhoid Business**: From 2024 to 2025, Mayinglong's hemorrhoid business is expected to benefit from channel optimization, with continuous positive growth in small and medium chain sales. The machine tool category is projected to grow by 23% in 2024, maintaining high double-digit growth in the first half of 2025. Enhanced control over first-level distributors and healthy inventory levels contribute to this growth [2][4]. - **Marketing Strategies**: The company employs comprehensive marketing strategies through online advertising and offline joint promotions to enhance brand awareness. Adjustments in pricing across different product categories and specifications are aimed at increasing revenue and profit margins [2][5]. - **Rapid Growth in Health Products**: The health consumer products segment, including wet toilet paper, has seen sales exceed 100 million yuan since its launch, performing exceptionally well in the e-commerce sector. The Baobao eye cream also achieved high double-digit growth in the first half of the year [2][6]. - **Financial Health**: As of the end of the second quarter, Mayinglong reported approximately 2 billion yuan in cash, maintaining a dividend payout ratio of 50%. The cash flow situation is robust, with accounts receivable and inventory at healthy levels. The company anticipates steady profit growth this year, driven by channel optimization and price increase measures leading to year-on-year growth in pure sales [2][7]. - **Competitive Advantage in the OTC Market**: Mayinglong demonstrates strong resilience in the OTC channel, maintaining high-quality double-digit growth despite pressures. The low-price, high-frequency consumption model creates stable demand, as consumers frequently purchase products that alleviate symptoms but do not provide a one-time cure [3][8][9]. Additional Important Insights - **Channel Optimization**: The focus on optimizing core channels and enhancing cooperation with medium and large chains and distribution dealers has yielded significant results in the hemorrhoid business [4]. - **Future Performance Expectations**: For the third quarter of 2025, Mayinglong is expected to continue high single-digit growth, with further acceleration anticipated in the fourth quarter due to price increases implemented after October 1 [3]. This summary encapsulates the essential insights from the conference call, highlighting Mayinglong's strategic focus, financial health, and competitive positioning within the industry.

Core Viewpoint - The stock of Mayinglong Pharmaceutical has shown positive performance with a year-to-date increase of 11.10% and a recent rise of 7.35% over the last five trading days, indicating strong market interest and potential growth in the pharmaceutical sector [1][2]. Financial Performance - For the first half of 2025, Mayinglong achieved a revenue of 1.949 billion yuan, reflecting a year-on-year growth of 1.11%, while the net profit attributable to shareholders was 343 million yuan, up by 10.04% [2]. - Cumulatively, since its A-share listing, Mayinglong has distributed a total of 1.633 billion yuan in dividends, with 591 million yuan paid out in the last three years [3]. Shareholder and Market Activity - As of June 30, 2025, the number of shareholders decreased by 23.07% to 31,100, while the average number of circulating shares per person increased by 29.98% to 13,825 shares [2]. - The stock's trading activity on October 14 showed a net inflow of 2.0038 million yuan from main funds, with significant buying and selling activity from large orders [1]. Company Overview - Mayinglong Pharmaceutical, established on May 9, 1994, and listed on May 17, 2004, is based in Wuhan, Hubei Province. The company specializes in drug manufacturing, retail, wholesale, and medical services [1]. - The main revenue sources for Mayinglong include treatments for hemorrhoids (45.53%), retail and wholesale (34.93%), other services (16.43%), and hospital diagnosis and treatment (3.11%) [1].

Core Viewpoint - The Chinese Medicine ETF (560080) has shown resilience despite a recent market downturn, with significant capital inflow and a leading position in its category [1][7]. Market Performance - The Chinese Medicine ETF (560080) experienced a nearly 1% decline after a significant opening drop, with a total trading volume exceeding 110 million yuan [1]. - The ETF has seen a net inflow of over 170 million yuan in the last 10 days, bringing its total size to nearly 2.4 billion yuan, leading its peers [1]. Component Stocks - Most component stocks of the Chinese Medicine ETF (560080) closed in the red, with notable declines including Jilin Aodong (-1.44%), Yunnan Baiyao (-1.01%), and Dong'e Ejiao (-1.22%) [3][4]. Yearly Index Performance - The Chinese Medicine Index has shown negative returns year-to-date, with a decline of 3.27% this year and an 8.13% drop in 2024, marking a four-year streak of negative annual performance [4]. Valuation Metrics - The TTM price-to-earnings ratio for the Chinese Medicine ETF (560080) stands at 25.11, which is at the 22.28% percentile of the past decade, indicating a more favorable valuation [6]. Leverage and Financing - Financing activities remain robust, with the latest financing balance for the ETF exceeding 84 million yuan, maintaining historical highs [7]. Industry Outlook - According to CITIC Securities, channel adjustments in the Chinese medicine sector are nearing completion, with expectations for demand recovery in the fourth quarter [9]. - The demand for traditional Chinese medicine products is anticipated to stabilize, with a gradual recovery expected as external pressures ease [9]. New Drug Developments - The number of new drug applications in the Chinese medicine sector is on the rise, with 92 new IND applications and 42 NDA applications reported in the first nine months of 2025 [10][12]. - Recent approvals for new drugs from companies like Fangsheng Pharmaceutical and Tianzhihui are expected to contribute positively to their growth [12].

Core Viewpoint - Ma Yinglong's stock price has shown a positive trend with an 8.12% increase year-to-date, reflecting a stable performance in the pharmaceutical sector [1][2]. Financial Performance - For the first half of 2025, Ma Yinglong achieved a revenue of 1.949 billion yuan, representing a year-on-year growth of 1.11% [2]. - The net profit attributable to shareholders for the same period was 343 million yuan, marking a year-on-year increase of 10.04% [2]. Stock Market Activity - As of October 10, Ma Yinglong's stock price was 27.56 yuan per share, with a market capitalization of 11.88 billion yuan [1]. - The stock experienced a trading volume of 81.90 million yuan and a turnover rate of 0.70% [1]. - Over the past five trading days, the stock price increased by 4.79%, while it rose by 3.34% over the last 20 days [1]. Shareholder Information - As of June 30, the number of shareholders decreased by 23.07% to 31,100 [2]. - The average number of circulating shares per shareholder increased by 29.98% to 13,825 shares [2]. Dividend Distribution - Since its A-share listing, Ma Yinglong has distributed a total of 1.633 billion yuan in dividends, with 591 million yuan distributed over the past three years [3]. Institutional Holdings - As of June 30, Hong Kong Central Clearing Limited was the third-largest circulating shareholder, holding 12.3912 million shares, an increase of 132,400 shares from the previous period [3]. - New institutional shareholders include Fortune Tianhui Growth Mixed Fund and Huatai-PineBridge Healthcare Mixed Fund, indicating growing interest from institutional investors [3].